The latent sensitization model of chronic pain reveals that recovery from some types of long-term hyperalgesia is an altered state in which nociceptive sensitization persists but is suppressed by the ongoing activity of analgesic receptors such as m-opioid receptors (MORs). To determine whether these MORs are the ones present in nociceptive afferents, we bred mice expressing Crerecombinase under the Na v 1.8 channel promoter (Na v 1.8cre) with MOR-floxed mice (flMOR). These Na v 1.8cre/flMOR mice had reduced MOR expression in primary afferents, as revealed by quantitative PCR, in situ hybridization, and immunofluorescence colocalization with the neuropeptide calcitonin gene-related peptide. We then studied the recovery from chronic pain of these mice and their flMOR littermates. When Na v 1.8cre/flMOR mice were injected in the paw with complete Freund adjuvant they developed mechanical hyperalgesia that persisted for more than 2 months, whereas the responses of flMOR mice returned to baseline after 3 weeks. We then used the inverse agonist naltrexone to assess ongoing MOR activity. Naltrexone produced a robust reinstatement of hyperalgesia in control flMOR mice, but produced no effect in the Na v 1.8/flMOR males and a weak reinstatement of hyperalgesia in Na v 1.8/flMOR females. Naltrexone also reinstated swelling of the hind paw in flMOR mice and female Na v 1.8cre/flMOR mice, but not male Na v 1.8cre/flMOR mice. The MOR agonist DAMGO inhibited substance P release in flMOR mice but not Na v 1.8cre/flMOR mice, demonstrating a loss of MOR function at the central terminals of primary afferents. We conclude that MORs in nociceptive afferents mediate an ongoing suppression of hyperalgesia to produce remission from chronic pain.
Introduction
Chronic pain disorders are not a mere exacerbation of acute pain but entail a switch of pain-processing mechanisms to a pathological state that may last indefinitely. Insight into the nature of this altered state has been provided by latent sensitization, a phenomenon observed in chronic pain studied in rodents 3, 11, 30, 43 that may also extend to humans. 34, 35 The key discovery of this conceptual model is that the apparent recovery that follows the hyperalgesia produced by certain injuries is not a return to normal pain transmission, but an altered state in which hyperalgesia persists but is suppressed by opioid receptor activation to produce remission. 11, 43 Thus, if opioid inverse agonists are administered during this state, there is a reinstatement of hyperalgesia lasting several hours. By contrast, opioid inverse agonists do not produce hyperalgesia in animals without latent sensitization. This resembles some forms of chronic pain in which pain appears in episodes. Several types of injury induce latent sensitization, including paw incision, 3, 37 complete Freund adjuvant (CFA), 11 carrageenan, 19 and nerve injury. 39 The fact that reinstatement of hyperalgesia by opioid antagonists can be repeated over months 3, 11 indicates that latent sensitization lasts indefinitely.
The molecular mechanisms of latent sensitization are being actively investigated. Maintenance of hyperalgesia involves Nmethyl-D-aspartate (NMDA) receptors, 4, 11 substance P, 38 and adenylyl cyclase. 11 Suppression of hyperalgesia is primarily mediated by m-opioid receptors (MORs), with additional contributions of d and k opioid, a 2A adrenergic and neuropeptide Y receptors. 3, 11, 39, 43 Mice with global MOR knockout (KO) do not fully recover from CFA-induced hyperalgesia, 43 showing that MORs suppress hyperalgesia in the remission phase of latent sensitization. However, the location of these receptors has not been determined. The objective of this study was to determine whether the MORs that suppress hyperalgesia in the remission phase of latent sensitization are present in nociceptive primary Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
afferents. Mice expressing Cre-recombinase under Na v 1.8 channel promoter control (Na v 1.8cre mice), which selectively express Cre in all nociceptive primary afferents, 42 were bred with mice in which the oprm1 gene is flanked by loxP sequences (flMOR mice) 44 to selectively eliminate MORs in nociceptors. We demonstrate that these receptors are crucial for the suppression of hyperalgesia during latent sensitization in a sexually dimorphic manner. m-Opioid receptors in primary afferents have important functions at their peripheral terminals and their central synapses. We also investigated the effect of MOR deletion at these 2 locations by studying naltrexone (NTX)-induced peripheral inflammation and MOR inhibition of substance P release at the central synapses.
Methods

Animals
All animal procedures were approved by the Animal Research Committee of UCLA and the Institutional Animal Care and Use Committee of the Veteran Affairs Greater Los Angeles Healthcare System, and conform to NIH guidelines. Experiments were designed to minimize the number of animals used and their suffering. Animals were provided food and water ad libitum and group-housed in a 12-hour light-dark cycle.
Mice with exons 2 and 3 of the oprm1 gene flanked by the LoxP cassette (flMOR), with a genetic background of 75:25% of C57BL/6: 129, 44 were provided by B.L.K. and C.G.-R. Mice expressing 1 allele of Cre-recombinase driven by the Na v 1.8 promoter (Na v 1.8cre), with C57BL/6 genetic background, were provided by Dr. John N. Wood. 44 Mice with flMOR on both alleles were bred with mice expressing 1 allele of Na v 1.8cre in the Animal Breeding Core of the Center for the Study of Opioid Receptors and Drugs of Abuse, UCLA. Genotyping was performed using samples of ear tissue by Transnetyx, Inc (Memphis, TN) by 2 independent assays for (1) flMOR on none, one, or both alleles and (2) the presence or absence of Cre-recombinase, using proprietary primer sequences.
Quantitative reverse transcription polymerase chain reaction
Quantitative RT-PCR (RT-qPCR) was performed as described 44 in Na v 1.8Cre/flMOR mice and flMOR mice. Mice were euthanized with 5% isoflurane followed by cervical dislocation and cortical tissue and pooled dorsal root ganglia from T13-L6 were dissected from individual mice into RNA Later solution (cat. no. AM7020; Invitrogen, Carlsbad, CA). RNA was purified with PureLinkTM RNA Mini Kit (cat. no. 12183018A; Invitrogen) and quantified with QubitTM RNA Broad Range Assay kit and QubitTM fluorometer (cat. no. Q10210; Invitrogen). RNA (1 mg) from each dorsal root ganglion (DRG) pool was reverse transcribed in a final volume of 20 mL using qScript cDNA supermix (cat. no. 95048; Quantabio, Beverly, MA). Quantitative PCR was performed on cDNA in quadruplicate (two 96-well plates containing duplicates were used) using PerfeCTa SYBR Green SuperMix Low Rox (cat. no. 95056; Quantabio) and QuantStudio3 (Applied Biosystems, Waltham, MA). PCR was performed with an initial 2-minute denaturation at 95˚C followed by 45 cycles of PCR (15 seconds at 95˚C and 45 seconds at 55˚C). Melt curve analysis performed at the end of PCR amplification reproducibly showed a single peak for each gene in each sample. Relative expression ratios (Na v 1.8Cre/flMOR vs flMOR) were calculated by using b-actin as a reference gene and the 2 2DDCt method to evaluate differential expression levels.
Primer sequences: 59-TGTGCACTTTTATTGGTCTC-39 (b-actin forward) 59-GATGTATGAAGGCTTTGGTC-39 (b-actin reverse) 59-TCAAGGCCCTGGATTTCCGTACCC-39 (oprm1 forward) 59-CGGGCAGACCAATGGCAGAAGAGA-39 (oprm1 reverse)
RNAscope in situ hybridization
Mice were euthanized with 5% isoflurane followed by cervical dislocation. Tissue was collected from the L2 to L6 dorsal root ganglia and snap-frozen in liquid nitrogen and embedded in optical coherence tomography (Fisher HealthCare, Carlsbad, CA). Tissue was sectioned at 16 mm and directly applied to gelatin-coated slides, prepared as previously described by submerging slides into a solution of 5 g of porcine gelatin (cat. no. 900-70-8; EMS brand, Hatfield, PA) dissolved at 45˚C in 1 L deionized H 2 O with 0.5 g chromium potassium sulfate dodecahydrate (CrK(SO 4 ) 2 ·12H 2 O) (Fisher Scientific, Carlsbad, CA). Tissue was fixed to the slides for 15 minutes in fresh 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) at 4˚C. Slides were dehydrated in a series of ethanol gradients at room temperature for 5 minutes each (50%, 70%, and 100%). The workflow was then performed in accordance with the manufacturer's protocol for the RNAScope Multiplex Fluorescent Assay (Advanced Cell Diagnostics, Newark, CA). Riboprobes 426011-C2 and 315841 selectively bind to sequences contained within the murine scn10a and oprm1 genes, respectively. The oprm1 and scn10a riboprobes were labeled with Atto550 and Alexa Fluor 488 fluorophores, respectively.
Immunohistochemistry
Mice were euthanized with pentobarbital (100 mg/kg) and fixed by aortic perfusion of 100 mL phosphate buffer (0.1 M sodium phosphate, pH 7.4) with 0.01% heparin, followed by 200 mL of ice-cold fixative (4% paraformaldehyde and 0.18% picric acid in phosphate buffer). A segment of the lumbar spinal cord (L3-L4) or spinal cord slices were fixed with 4% paraformaldehyde, cryoprotected in 20% sucrose, embedded in Tissue-Tek (Sakura Finetek USA, Inc, Torrance, CA) and frozen onto coverslips on dry ice. Free-floating transversal sections (25 mm thick) were cut with a cryostat (Leica Biosystems, Buffalo Grove, IL). Sections were washed twice with PBS and twice with PBS containing 0.3% Triton X-100 (PBS/Triton) and 1% normal serum (goat or donkey; Jackson ImmunoResearch, West Grove, PA). Sections were incubated overnight in PBS/Triton containing 10% normal serum with primary antibodies (see below). Isolectin B4 (IB4)-biotin (5 mg/mL, Sigma-Aldrich, St. Louis, MO) was included in some experiments and detected using streptavidin-Alexa Fluor 488 (Invitrogen-Molecular Probes, Eugene, OR). After 3 washes with PBS, sections were incubated for 2 hours with secondary antibodies (1:2000): Alexa Fluor-488 goat anti-guinea pig IgG (Invitrogen-Molecular Probes), Alexa Fluor-568 goat anti-rabbit IgG (Invitrogen-Molecular Probes), and Alexa Fluor-594 donkey anti-guinea pig IgG (Jackson ImmunoResearch). After 4 more PBS washes, sections were mounted in Prolong Gold (InvitrogenMolecular Probes). All incubations and washes were performed at room temperature.
Primary antibodies: Calcitonin gene-related peptide (CGRP) (dilution 1:10,000) 27 : polyclonal rabbit antibody against rat CGRP [23] [24] [25] [26] [27] , VKDNFVPTNVGSEAF (Dr. Catia Sternini, Division of Digestive Diseases, UCLA).
MOR (dilution 1:1000) 7, 40 : Affinity-purified guinea pig antibody against the peptide sequence NHQLENLEAETAPLP, corresponding to amino acids 384 to 398 of the C-terminus of human MOR (GP10106; Neuromics, Edina, MN). NK1R (dilution 1:3000) 8, 9, 14 : Rabbit antiserum against amino acids 385 to 407 at the C-terminus of the rat NK1R (AB5060; EDM Millipore, Billerica, MA).
Substance P release measured as NK1R internalization
Spinal cord slices were prepared as previously described in rats. 1, 29 The spinal cord was extracted from adult mice under pentobarbital anesthesia (Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI). Coronal slices (400 mm, 3-4 per mouse) were cut from the lumbar spinal cord (L2-L4) with a Leica VT1000S vibratome (Buffalo Grove, IL). Slices were kept in artificial cerebrospinal fluid (aCSF), which contained (in mM) 124 NaCl, 1.9 KCl, 26 NaHCO 3 , 1.2 KH 2 PO 4 , 1.3 MgSO 4 , 2.4 CaCl 2 , and 10 glucose, oxygenated with 95% O 2 /5% CO 2 . Vibratome cutting was performed in sucrose-aCSF, which was the same aCSF medium with 5 mM KCl and 215 mM sucrose instead of NaCl. Slices were left to recover in oxygenated aCSF at 35˚C for 1 hour and then were incubated with drugs at 35˚C in 5 mL of aCSF. At the end of the experiment, slices were fixed in ice-cold fixative and processed for NK1R immunohistochemistry.
NK1R internalization was used as a measure in situ of substance P release, a method extensively validated. 1, 2, 15, 26, 29 NK1R neurons in lamina I were visually counted while classifying them as with or without internalization, using a Zeiss Axio-Imager A1 (Carl Zeiss, Inc, Thornwood, NY) fluorescence microscope with a 633 (1.40 numerical aperture) objective. The criterion for having internalization was the presence of 10 or more NK1R endosomes. The person counting the neurons was blinded to the treatment and genotype. Results were expressed as the percentage of the NK1R neurons in lamina I with NK1R internalization.
Confocal microscopy
Confocal images were acquired using a Zeiss LSM 710 microscope (Carl Zeiss, Inc), with objectives of 203 (numerical aperture 0.8) and 633 oil (numerical aperture 1.4). Laser excitation lines and emission windows were: Alexa Fluor 488, excitation 488 nm, emission 500 to 540 nm; Alexa Fluor 568, excitation 561 nm, emission 580 to 630 nm; Alexa Fluor 594, excitation 561 nm, emission 500 to 677 nm; and Atto 550, excitation 561 nm, emission 570 to 648 nm. The pinhole was set to 1.0 Airy unit for each objective and fluorophore. The separation between optical sections was 0.85 mm or 0.99 mm for the 203 objective and 0.38 mm for the 633 objective, as determined by microscope software using the Nyquist formula. Imaris 6.1.5 (Bitplane AG, Zurich, Switzerland) was used to crop the image stacks. Adobe Photoshop 5.5 (Adobe Systems Inc, Mountain View, CA) was used to adjust the gamma and to assemble the multipanel figures.
Image analysis
In situ hybridization
Three DRG histological sections per mouse were imaged with the confocal microscope using the 203 objective, obtaining stacks of 3 optical sections separated 0.99 mm. Because there were 4 groups of mice with n 5 4 mice per group, a total of 48 confocal stacks were obtained. Fiji/ImageJ (1.51n, Wayne Rasband, National Institutes of Health) with a cell counter plugin (Kurt De Vos, University of Sheffield, United Kingdom) was used to count cell profiles in the middle optical section of each stack. Cells marked with the scn1a or oprm1 probes were counted first, and then those labeled with both probes. The percentage of scn1a cells positive for oprm1 was then calculated. Data from the 3 histological sections from each mouse were averaged and taken as the value for that mouse. The investigator taking the confocal images and counting the cells was blinded towards genotype and sex corresponding to each sample.
Intensity of m-opioid receptor immunofluorescence
A single-optical section was chosen in the middle of the confocal stack, and MOR staining was measured as the integrated intensity using Fiji/ImageJ. For images taken at 203, measures were taken in a region of interest drawn by hand to encompass the entire superficial dorsal horn (laminae I-II). In images at 633, measures were taken on the entire optical section. Measures of integrated intensity were taken for pixels over an intensity threshold value of 50 (203) or 40 (633) in a scale of pixel intensity of 0 to 255.
Colocalization of 2 immunofluorescence labels in the dorsal horn
This was measured in whole confocal stacks (voxel-by-voxel) using Imaris, as previously described. 27 Briefly, threshold pixel intensity values were set for each label (40 for MOR, 20 for CGRP, and 20 for IB4), and colocalization was measured as the Pearson correlation coefficient of the pixels above this threshold.
Complete Freund adjuvant injection
Complete Freund adjuvant (5 mL, undiluted; Sigma-Aldrich) was injected subcutaneously (s.c.) in the right hind paw using a 50-mL Hamilton syringe and a 26 G needle, as described. 30, 43 The needle was inserted at an oblique angle from the heel in the middle of the paw, near the base of the third toe. It was held in place for 15 seconds and then gently withdrawn.
Mechanical allodynia measurements
As an indicator of the hyperalgesia produced by CFA 6, 16 or its reinstatement by antagonists, 39 we measured mechanical allodynia using von Frey filaments. 5 After 3 days of habituation to the tester and the testing room, mice were habituated for 30 minutes to acrylic enclosures on an elevated metal grid (10 3 10 3 12 cm, IITC Life Sciences, Woodland Hills, CA). A set of calibrated plastic von Frey filaments (Touch-Test; North Coast Medical, Inc, San Jose, CA) was then used to measure allodynia by the up-down method. Data were analyzed using the Dixon algorithm 12 to obtain the 50% paw withdrawal threshold (PWT) in grams. Baseline PWT measures were taken for 5 days before CFA injection, as well as the day of injection. Then, the PWT was measured at days 1, 3, 7, 14, 21, 28, 35, 40, and 52 after CFA. 43 To assess reinstatement of allodynia, mice were given 3 mg/kg s. c. NTX (Sigma-Aldrich) or 1 mg/kg s.c. BRL44408 (Tocris Bioscience, Bristol, United Kingdom), and PWT was measured at 20, 40, 60, 90 minutes, and 24 hours.
The study consisted of 2 groups: Na v 1.8cre/flMOR mice (male, n 5 8; female, n 5 6) or their flMOR littermates (male, n 5 7; female, n 5 8). Sample size was targeted at 16 mice per genotype based on a power analysis of previous data, 43 indicating that n 5 14 is needed for 0.8 power and that n 5 18 yields 0.9 power. To study sex differences, each of these 2 groups was subdivided into males and females. Two cohorts of mice, each consisting of approximately the same number of mice from each group and sex, were ran at different times. The mice in each cohort were matched by age (30-40 days) and sex. The experimenter was blinded regarding the group to which each mouse belonged.
Measures of paw edema
The mouse was gently restrained by one investigator, whereas another measured the dorsal-plantar distance of the hind paw at the metatarsal level using digital calipers (Vinca, 0-150 mm, 0.1 mm precision). 32 Paw edema reported as paw thickness (mm) was assessed at days 0, 1, 3, 7 after CFA injection, and at times 0, 20, 40, 60, 90, and 120 minutes after NTX injection.
Data analysis
Data were analyzed using Prism 7.03 and 8.00 (GraphPad Software, San Diego, CA) and expressed as mean 6 SE. Statistical significance was set at 0.05. Experiments with 1 variable were analyzed by the t test or 1-way analysis of variance (ANOVA), as appropriate. Other statistical analyses consisted of repeated-measures 2-way ANOVA ( Table 1) with Holm-Sidak post hoc tests and repeated-measures 3-way ANOVA ( Table 2) , assuming sphericity.
Results
Decrease in m-opioid receptor mRNA in dorsal root ganglion neurons: reverse transcription-quantitative polymerase chain reaction
To determine the decrease in expression of MOR mRNA in nociceptive primary afferents, we performed RT-qPCR for oprm1 (MOR) mRNA 44 in the DRG (T13-L6, pooled) and the brain cortex of flMOR mice (n 5 8) and Na v 1.8cre/flMOR mice (n 5 9). Expression of b-actin was used as the reference. We found that expression of oprm1 significantly decreased in the DRG of Na v 1.8cre/flMOR mice compared with flMOR mice, whereas no differences between these genotypes were found in the cortex (Fig. 1). 3.2. Decrease in m-opioid receptor mRNA in dorsal root ganglion neurons expressing Na v 1.8 channels: in situ hybridization A second measure of the decrease in expression of MORs in nociceptive primary afferents in the Na v 1.8cre/flMOR mice relative to their flMOR littermates was in situ hybridization. Because the elimination of MORs was targeted to DRG neurons expressing Na v 1.8 channels, we used oprm1 (MOR) and scn10a (Na v 1.8) riboprobes. There was a large number of cell bodies expressing both scn10a and oprm1 in the L2 to L6 DRG of the flMOR mice ( Fig. 2A) , which markedly decreased in the Na v 1.8cre/flMOR mice (Fig. 2B) . To quantify this decrease and study possible sex differences, DRG (T13-L6) was harvested from 4 male and 4 female mice of each genotype. Confocal images were obtained from 3 DRG histological sections from each mouse. The percentage of cells expressing both scn10a and oprm1 relative to the total number of cells expressing scn10a was obtained for each DRG section. Results from the 3 sections from each mouse were averaged and taken as a value for that mouse. The resulting data were then analyzed by 2-way ANOVA ( Table 1  row 1) . There was a large decrease in the percentage of DRG cells expressing scn10a that also expressed oprm1 in the Na v 1.8cre/ flMOR mice relative to their flMOR littermates (Fig. 2C) . However, a few DRG cells expressing both mRNAs remained in the Na v 1.8cre/flMOR mice. No sex differences were observed, indicating that the elimination of MORs in nociceptive afferents was similar in both sexes.
3.3. Decrease in m-opioid receptors in primary afferents in the dorsal horn: immunohistochemistry A guinea pig antibody against MORs (Neuromics GP10106) was used to assess changes in MOR immunoreactivity in the dorsal horn of these mice. This antibody produced a distinct staining of cells and fibers in laminae I and II (Fig. 3 ) similar to that found in rats. 7, 40, 41 However, this and other MOR antibodies tested produced artefactual staining of mouse DRG neurons that persisted in global MOR KO mice (data not shown). To assess the elimination of MORs in primary afferents, we studied the colocalization of MORs with CGRP and isolectin B4 (IB4), which label 2 populations of primary afferents encompassing most nociceptors. 42 Images of the whole dorsal horn taken with a 203 objective showed MOR staining throughout laminae I and II in the flMOR mice (Fig. 3A) , whereas in the Na v 1.8cre/flMOR mice, there was a decrease in MOR staining in a band corresponding to outer lamina II (Fig. 3B) . At this magnification, however, MORintegrated intensity in laminae I and II was not significantly different between Na v 1.8cre/flMOR mice and their flMOR littermates (Fig. 3C) . The difference in MOR staining became conspicuous when using a 633 objective (Figs. 3D and E), with a statistically significant decrease in MOR-integrated intensity in Na v 1.8cre/flMOR mice compared with flMOR mice (Fig. 3F) .
To determine whether the decrease in MOR immunoreactivity occurred in the primary afferents, we measured the colocalization of MOR with CGRP and IB4 in confocal stacks taken at 633. Qualitatively, there was a decrease in puncta positive for both MOR and CGRP in the superficial dorsal horn of Na v 1.8cre/flMOR mice (Figs. 3D and E). Quantitatively, CGRP/MOR colocalization was measured as the Pearson correlation coefficient, which showed a positive colocalization and decreased significantly in Na v 1.8cre/flMOR mice compared with their flMOR littermates (Fig. 3G) . In contrast, there was no colocalization of MOR and IB4 staining (Figs. 3H and I) , with a Pearson correlation coefficient of 20.0004 6 0.0064 (n 5 6 images from 3 flMOR mice, 2 images/ mice). We concluded that in the Na v 1.8cre/flMOR mice there is a selective decrease of MORs in CGRP-containing primary afferent fibers in the dorsal horn.
Mice lacking m-opioid receptors in nociceptors do not recover from mechanical hyperalgesia
Once we established that MORs were deleted from nociceptors in the Na v 1.8cre/flMOR mice, we studied how these mice recovered from CFA-induced hyperalgesia. Na v 1.8cre/flMOR mice and their flMOR littermates were injected with CFA in 1 hind paw. To study sex differences, each genotype was subdivided by sex, resulting in 4 groups of n 5 8. Two female Na v 1.8cre/flMOR mice and 1 male flMOR mouse died during the experiment, reducing the n of these groups to 6 and 7, respectively. Baseline responses to von Frey filaments were measured daily for 5 days.
No differences between genotypes and sexes, and no drift in the baseline were observed (Fig. 4A and Table 1 row 2) . After injection of CFA (5 mL s.c., undiluted) in 1 hind paw, all mice developed strong mechanical hyperalgesia. Whereas in the flMOR mice the hyperalgesia subsided back to baseline levels by day 21; in the Na v 1.8cre/flMOR mice the recovery was incomplete, with substantial levels of hyperalgesia remaining 52 days after CFA (Fig. 4A) . Two-way ANOVA yielded significant effects of time, genotype, and their interaction, either when data of both sexes were combined (Table 1 row 3) , or when data from males and females were analyzed separately (Table 1 rows 4 and 5). To detect any sex differences, the data were separated by sex and analyzed by 3-way ANOVA (Table 2 row 1), which yielded no significant effect of sex or any significant interaction of sex with the other 2 variables, time and genotype. Although PWT measures seemed consistently lower in male relative to female Na v 1.8cre/flMOR mice (Fig. 4A) , area under the curve analyses indicated no significant sex differences: male 18.6 6 1.5 (n 5 8), female 26.0 6 3.7 (n 5 6); the t test, P 5 0.063, t 5 2.05, df 5 12. We concluded that deleting MORs from nociceptive afferents prevents the full recovery from CFAinduced hyperalgesia. There was, however, a partial recovery from mechanical hyperalgesia in the Na v 1.8cre/flMOR mice. To determine whether this recovery was mediated by MORs other than the ones present in nociceptors, mice of both genotypes were injected with the MOR inverse agonist NTX (3 mg/kg s.c.) on day 40 after CFA. In the flMOR mice, either male (Fig. 4B) or female (Fig. 4C) , NTX produced a marked hyperalgesia that disappeared after 24 hours. In the Na v 1.8cre/flMOR mice, NTX produced no significant effect in the males (Fig. 4B) and a small but statistically significant hyperalgesia in the females (Fig. 4C) . When sexes were combined, the difference in the effect of NTX between genotypes was highly significant (Table 1 row 6). Two-way ANOVAs separating sexes yielded significant effect of genotype for males (Table 1 row 7) but not for females (Table 1 row 8). Sex differences were studied using 3-way ANOVA (Table 2 row 2), which yielded very significant effects of time, genotype, and their interaction. Although there was no significant effect of sex, the interaction of sex with genotype and of the 3 variables was significant. We concluded that in the male Na v 1.8cre/flMOR mice the partial recovery from hyperalgesia (Fig. 4A) is not mediated by MORs, whereas in the female Na v 1.8cre/flMOR mice this recovery from hyperalgesia could be mediated by MORs located in places other than primary afferents, possibly in dorsal horn neurons or the brain.
To examine the possibility that the partial recovery from hyperalgesia in the Na v 1.8cre/flMOR mice is mediated by a 2A adrenergic receptors, 43 we determined whether it was eliminated by the selective a 2A adrenergic antagonist BRL44408. 21, 33 Indeed, BRL44408 (1 mg/kg s.c.) induced a marked increase of hyperalgesia in both the flMOR and the Na v 1.8cre/flMOR mice, male and female (Figs. 4D and E) . The effect of BRL44408 was significant in both when results were combined by sex (Table 1 row 9) or segregated by sex (Table 1 rows 10 and 11). Three-way ANOVA showed that there are no sex differences in the effect of BRL44408 (Table 2 row 3).
Reinstatement of paw swelling by naltrexone
The initial injection of CFA in the hind paw produced a notable swelling, which was maximal on day 1 and decreased gradually afterwards (Fig. 5A) . This edema was measured as an increase in the dorsoventral thickness of the paw. Two-way ANOVA ( Table 1 row 12) revealed a significant effect of CFA but not of genotype (flMOR vs Na v 1.8cre/flMOR) or their interaction.
When NTX was injected without a previous injection of CFA, it did not produce any edema in either the flMOR or the Na v 1.8cre/ flMOR mice (Fig. 5B) . Analysis of variance yielded no significant effects of NTX, genotype, or their interaction (Table 1 row 13) .
However, when NTX was injected to flMOR mice previously injected with CFA, there was a marked edema of the injected hind paw (Figs. 5C and D) . This effect occurred a long time after the injection of CFA (up to 80 days), which suggests that in mice with latent sensitization MORs suppress not only hyperalgesia but also swelling of the peripheral tissues. In Na v 1.8cre/flMOR mice there was a remarkable sex difference in the effect of NTX after CFA. Naltrexone produced no edema in the males (Fig. 5C) , whereas in the females it produced edema like in the flMOR mice (Fig. 5D) . Two-way ANOVA of the data from male mice ( Table 1 row 14) yielded no significant effect of genotype but a significant interaction of genotype with the effect of NTX, whereas in female mice ( Table 1 row 15) there was a significant effect of NTX but not of genotype or their interaction.
To confirm this sex difference in the NTX-induced edema, we increased the sample size by adding new cohorts to these 4 groups of mice. Edema was measured before NTX (0 minutes) and 60 minutes after NTX, and data were combined with the same time points of Figures 5C-D . This confirmed that NTX increased paw thickness in the flMOR mice, male and female, and in the Na v 1.8cre/flMOR female mice, but not in the Na v 1.8cre/flMOR male mice (Fig. 5E ). Results were analyzed by 3-way ANOVA (Table 2 row 4), which yielded significant effects of the variables time (effect of NTX) and sex, but not genotype. However, there was a significant 3-way interaction between the variables, indicating that the sex difference was related to genotype. Two-way interactions were not significant. In conclusion, NTX-induced edema disappeared in the male but not the female Na v 1.8cre/flMOR mice.
3.6. m-Opioid receptor inhibition of substance P release was eliminated in Na v 1.8cre/flMOR mice To study the effect of MOR depletion in nociceptors on their central synapses, we evaluated the inhibition of substance P release by the MOR agonist DAMGO. 8, 18 Substance P release was evoked by incubating spinal cord slices for 2 minutes with 10 mM NMDA 1 10 mM D-serine (D-Ser), to activate NMDA receptors in primary afferents that induce substance P release. 8, 9, 23, 25, 28, 31 Three spinal cord slices per mouse were obtained from flMOR mice (n 5 7, 3 males and 4 females) and Na v 1.8/flMOR mice (n 5 9, 4 males and 5 females). Mice were killed 53 to 57 days after CFA injection in the hind paw. Of the 3 slices obtained from each mouse, one was used as a control, another was incubated for 2 minutes with NMDA and D-Ser (both 10 mM), and the third was incubated for 60 minutes with 1 mM DAMGO and then for 2 minutes with NMDA1D-Ser. NK1R internalization in laminae I and II neurons was used as a measure in situ of substance P release. 8, 9, 23, 26 In the control slices, NK1R internalization was not significantly different between flMOR mice and Na v 1.8cre/flMOR (Fig. 6A, P 5 0 .064 in the Holm-Sidak post hoc test). In the slices incubated with NMDA1D-Ser, there was a similar increase in NK1R internalization in both genotypes (Fig.  6A) . In the slices preincubated with DAMGO, NMDA-induced NK1R internalization decreased in the flMOR mice but not in the Na v 1.8cre/flMOR mice ( Fig. 6A ; 2-way ANOVA in Table 1 row 16). Representative images of NK1R-positive dorsal horn neurons illustrating that the absence and presence of NK1R internalization are showed in Figures 6B-G. We concluded that MOR inhibition of substance P release was lost in the Na v 1.8cre/ flMOR mice.
Discussion
We found that mice with a selective depletion of MORs in nociceptive primary afferents do not recover from CFA-induced hyperalgesia. Therefore, this MOR population is required for the suppression of hyperalgesia in the chronic pain state, as represented by the latent sensitization model.
Validation of the m-opioid receptor knockout in nociceptive primary afferents
Evidence from multiple experimental approaches confirms the selective deletion of MORs in nociceptive afferents in the Na v 1.8cre/flMOR mice, as shown by Weibel et al. 44 in a Na v 1.8-cre/flMOR line generated independently. First, real-time RTqPCR showed that oprm1 mRNA was decreased in the DRG but not in the brain cortex of these mice. Second, RNAscope in situ hybridization showed that in these mice, oprm1 mRNA was depleted from DRG neurons expressing scn10a mRNA for Na v 1.8 channels, which are expressed by all nociceptive primary afferents. 42 We found that 14% of the scn10a-positive DRG neurons also expressed oprm1 in the Na v 1.8cre/flMOR mice, down from 33% in the flMOR mice, indicating a predominant but not total MOR KO in Na v 1.8-expressing primary afferents. Third, immunofluorescence double-labeling in the dorsal horn showed a substantial decrease of MOR immunoreactivity in fibers containing the neuropeptide CGRP, which is expressed by peptidergic (PEP1 and PEP2) as well as some nonpeptidergic (NP2) primary afferents. 42 By contrast, MOR immunoreactivity in dorsal horn neurons was not changed in the Na v 1.8cre/flMOR mice, showing that MOR elimination is specific to the primary afferents. We found that MORs do not colocalize with IB4 staining, which is consistent with reports that MOR immunoreactivity and function is lower in IB4-binding primary afferents. 17, 46 In another study, 10 MORs were eliminated from nociceptive primary afferents by using TRPV1cre mice instead of the Na v 1.8cre mice used by Weibel et al. 44 and by us. Both lines were crossed with the same flMOR mice. 44 Like the Na v 1.8cre/ flMOR mice, the TRPV1cre/flMOR mice showed a marked reduction of MOR immunoreactivity in CGRP-containing primary afferents. However, the distribution of MOR immunoreactivity in the dorsal horn was somewhat different in these 2 lines: the TRPV1cre/flMOR mice show a large decrease in MORs in lamina I that we did not find in the Na v 1.8cre/flMOR mice. Hence, these 2 mouse lines do not seem to deplete MORs from the exact same populations of primary afferents.
Effect of m-opioid receptor knockout in nociceptors on complete Freund adjuvant-induced hyperalgesia
The main finding of this study is that mice with the selective MOR depletion in nociceptors do not recover from the mechanical hyperalgesia induced by CFA injection. Although there was a partial recovery, almost 2 months after CFA these mice had only recovered to half their baseline withdrawal thresholds. These results are similar to those that we obtained using mice with global MOR KO, 43 showing that the MORs that suppress hyperalgesia in latent sensitization are in nociceptive afferents. However, unlike global MOR KO mice, Na v 1.8cre/flMOR mice showed a sex-dependent (in females but not in males) induction of hyperalgesia by NTX, which is used to define the presence of constitutively active MORs. 11, 43 This sex difference was not caused by a different extent of deletion of MORs in nociceptive afferents, which was shown to be the same in males and females by in situ hybridization. Therefore, we concluded that in male mice the MORs that suppress hyperalgesia are located in nociceptive afferents, whereas in females there is some contribution of MORs located in dorsal horn neurons or supraspinally. More complex phenomena, such as different heterodimerization of MORs and k-opioid receptors in males and females, 24 could also explain our observations.
In contrast to NTX, the a 2A adrenergic antagonist BRL44408 produced a robust reinstatement of hyperalgesia in both male and female Na v 1.8cre/flMOR mice, confirming that these mice had latent sensitization. Together with a previous study, 43 these results indicate that the partial suppression of hyperalgesia in the Na v 1.8cre/flMOR mice is mediated by a 2A receptors, likely in addition to d-and k-opioid receptors.
Paw swelling produced by naltrexone
Another important finding is that NTX induces swelling of the hind paw long after it was injected with CFA. This shows that latent sensitization not only manifests itself as a reinstatement of hyperalgesia but also as reappearance of inflammation. This could be caused by inhibition by NTX of MORs present in peripheral nerve terminals and immune cells in the paw that suppress inflammation. Alternatively, blockade by NTX of MORs in the central terminals of primary afferents could suppress their disinhibition and trigger retrograde signals that produce neurogenic inflammation. 20, 22 Both effects could take place: studies of migraine headache show that MORs block distension of meningeal blood vessels by both peripheral and central mechanisms. 45 Interestingly, we found that although NTX produced edema in female Na v 1.8cre/flMOR mice with latent sensitization, it did not produce any edema in the males. This indicates that the MORs that suppress inflammation are located in primary afferents in males but not in females. It is possible that in Na v 1.8cre/flMOR male mice the inflammation-suppressing role of MORs has been taken over by other receptors. A well-known effect of MORs at the central synapse of primary afferents is to inhibit neurotransmitter release, 13 in particular that of substance P. 8, 18, 47 This effect is mediated by the inhibition of voltage-gated Ca 21 channels and NMDA receptors in the presynaptic terminals. 8, 48 Here, we show that MOR inhibition of NMDA receptor-induced substance P release is absent in the Na v 1.8cre/flMOR mice. This demonstrates that in these mice there is a loss of MOR function in the central synapse of peptidergic primary afferents, which is likely to contribute to the loss of MOR suppression of hyperalgesia. Thus, maintenance of Table 1 . Holm Sidak post hoc tests: *P , 0.05, **P , 0.01, ***P , 0.001 compared with flMOR mice of the same sex (A) or with baseline measures (0 minutes) (B-E). Three-way ANOVA results for panel (A) and combined panels (B and C) and (D and E) are in Table 2 . ANOVA, analysis of variance; MOR, m-opioid receptor.
hyperalgesia in latent sensitization requires the activation of spinal NMDA receptors 11, 36 and neurokinin 1 receptors. 38 Furthermore, MORs in primary afferent terminals inhibit NMDA receptors by inhibiting the adenylyl cyclase-protein kinase A pathway, 8 which is also essential for latent sensitization. 11 Therefore, the central terminals of nociceptive afferents may be the location of the were injected with NTX (3 mg/kg s.c.) 53 to 57 days after CFA and the resulting edema in the ipsilateral hind paw was measured at the times indicated. (D) Female Na v 1.8cre/flMOR mice (n 5 6) and flMOR mice (n 5 8) were injected with NTX (3 mg/kg s.c.) 53 to 57 days after CFA, and the edema in the ipsilateral hind paw was measured. The dotted line indicates average baseline paw thickness. (E) Other cohorts of flMOR and Na v 1.8cre/flMOR mice, male and female, were injected with CFA in the hind paw and then with NTX (3 mg/kg s.c.) 35 days later. Paw thickness measures were taken just before NTX (0 minutes) and 60 minutes later, and then aggregated with measures at the same times from panels (C and D). Each point is from a different mouse and numbers in the bars are number of mice (n). Two-way ANOVA results are in Table 1 . Holm Sidak post hoc tests: *P , 0.05, **P , 0.01, ***P , 0.001 compared with time 0 days or 0 minutes of mice of the same genotype. Three-way ANOVA of panel (E) is in Table 2 Table 1 molecular mechanisms for both the maintenance of hyperalgesia and its suppression by opioid receptors in latent sensitization.
Physiological and therapeutic implications
The most important conclusion from this study is that MORs in primary afferents play a crucial role in suppressing hyperalgesia in latent sensitization. If we assume that latent sensitization is a valid model of chronic pain, then these MORs are essential for keeping pain in check in chronic pain disorders. Therefore, using peripherally restricted MOR antagonists to avoid the development of MOR tolerance and opioid-induced hyperalgesia in patients with chronic pain, as recently suggested, 10 may result in an increase in pain. However, this would depend on whether MORs on nociceptors produce this pain-suppressing effect at their central or their peripheral terminals. If pain suppression occurs only at the central terminals, which are protected by the blood-brain barrier, then peripherally restricted MOR antagonists would not affect it. In fact, Corder et al. 11 found that systemic administration of the peripherally restricted MOR inverse agonist NTX methobromide did not reinstate hyperalgesia in mice with CFA-induced latent sensitization. Together with our results, this indicates that the pain-suppressing effect of MORs occur at the central synapse of primary afferents and not at their peripheral terminals. This seems to be inconsistent with the analgesic role of MORs in peripheral terminals reported by Weibel et al., 44 who found that the peripherally restricted MOR agonist loperamide alleviated inflammatory hypersensitivity and that this was blocked by the peripheral opioid antagonist naloxone methiodide. However, the study by Weibel et al. was conducted 2 days after CFA injection and activated MORs with loperamide, whereas the study by Corder et al. 11 was conducted in mice with latent sensitization, weeks after CFA injection and without agonist activation of MORs because they are in a constitutively active state. 11, 43 Taken together, these observations suggest that MORs in the central synapse of primary afferents are the ones that suppress hyperalgesia in latent sensitization by becoming constitutively active, whereas MORs in the peripheral terminal contribute to the analgesic effect of opiates in the inflammatory state. The neuronal and molecular mechanisms that maintain MORs in the constitutively activated state are still unknown, but locating them at the central primary afferent terminals will facilitate their study.
